Recognition of Mtb-Infected Cells by Non-Classically Restricted CD8+ T Cells
Recognition of Mtb-Infected Cells by Non-Classically Restricted CD8+ T Cells
批准号:
10554259
负责人:
DAVID M. LEWINSOHN
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2024-12-31
关键词:
AccountingAnabolismAntigensCD8-Positive T-LymphocytesCategoriesCell surfaceCellsCessation of lifeClinicalCollaborationsCommunicable DiseasesDataDevelopmentDiagnosticEndosomesEnvironmentExposure toExtended FamilyFamilyFundingGrantHouseholdHumanImmune responseImmune systemInfectionIntestinesLaboratoriesLearningLigandsLocationLungMacrophageMemoryMolecularMolecular ChaperonesMorbidity - disease rateMucous MembraneMycobacterium tuberculosisOrganismOutcomePeptidesPlayPopulationPredispositionPrevalenceProcessProgram ReviewsProteinsRNA SplicingResearch ProposalsResistance to infectionRiboflavinRoleSamplingT-LymphocyteThymus GlandTissuesTuberculosisUmbilical Cord BloodUniversitiesVaccinesVariantVesicleVitamin B ComplexWashingtonWorkclinically relevantdirect applicationimprovedmicrobialmortalitymycobacterialpathogenprogramsresponsesmall moleculetraffickingtuberculosis immunityuptake
中文摘要
项目摘要
结核病(TB)是全球传染病死亡的主要原因,占新增病例的1040万
每年有130万人死亡。了解结核分枝杆菌的免疫反应是至关重要的。
在改进的疫苗的开发中。在这方面,我们的实验室在退伍军人事务部的赞助下
程序将粘膜相关不变T细胞(MAIT)定义为一类受
高度保守的mr1分子识别结核分枝杆菌感染的细胞,在胸腺和脐带具有效应能力。
血液,但在接触结核分枝杆菌后表现出记忆的证据,并在肺中浓缩。
MAIT细胞存在于肺和肠道等组织中。因为MAIT细胞识别小分子,
如核黄素的代谢物,我们推测MR1的细胞表面表达受到严格调控
避免在没有细胞内感染的情况下激活这些细胞。事实上,在退伍军人事务部的支持下
程序中,我们发现MR1既位于内吞体内,又需要一个配体才能转运到细胞中
表面,并依赖于囊泡运输将结核分枝杆菌衍生的抗原呈递给MR1T细胞。
此外,我们发现,结核分枝杆菌衍生抗原的呈递机制是可以区分的。
从外源性传递的抗原中分离出来,这表明有专门的采样机制
细胞内环境。
因此,在本申请中,我们将重点定义允许适当的
细胞内感染的表现,重点是结核分支杆菌。我们将1)定义所需的分子伴侣
用于呈现微生物配体,以及2)定义MR1 SNPs和剪接变异体在控制中的作用
结核分枝杆菌感染细胞的识别,并将评估这些变异在以下临床相关结果中的作用
暴露于结核杆菌。
该项目包含两个目标:
目标1:确定Mtb衍生配体呈递所需的分子伴侣
1A.确定与MR1相关的分子伴侣。
1B.确定核黄素转运体在MR1配体摄取或运输中的作用。
目标2:确定MR1单核苷酸多态和剪接变异体在人类结核病易感性中的作用
2A。确定MR1单核苷酸多态和剪接变异体与临床预后的关系
暴露于结核杆菌。
2B。确定MR1单核苷酸多态的功能意义。
2C。确定MR1剪接变异体表达与细胞呈递MR1能力的关系
与MR1T细胞的配基。
英文摘要
Project Summary
Tuberculosis (TB) is a leading cause of infectious disease mortality worldwide, accounting for 10.4 million new
cases and 1.3 million deaths annually. An understanding of the immune response to Mtb is of central importance
in the development of improved vaccines. In this regard our laboratory, under the auspices of the VA Merit
Program, has defined Mucosal Associated Invariant T (MAIT) cells as a class of cells that are restricted by the
highly conserved MR1 molecule, recognize Mtb-infected cells, have effector capacity in the thymus and cord
blood, yet display evidence for memory following exposure to Mtb, and are enriched in the lungs.
MAIT cells are found in tissues such as the lung and intestine. Because MAIT cells recognize small molecules,
such as metabolites of riboflavin, we postulate that the cell surface expression of MR1 is tightly regulated to
avoid activation of these cells in the absence of intracellular infection. Indeed, with the support of the VA Merit
Program, we have found that MR1 is both located in an endosome, requires a ligand for translocation to the cell
surface, and is dependent on vesicular trafficking for the presentation of Mtb-derived antigens to MR1T cells.
Furthermore, we find that the mechanisms underlying presentation of Mtb-derived antigens can be distinguished
from antigens that are exogenously delivered, suggesting that there are specialized mechanisms for sampling
the intracellular environment.
Therefore, in this application we will focus on defining the molecular mechanisms that allow for the appropriate
presentation of intracellular infection, with a focus on Mtb. We will 1) Define the molecular chaperones required
for the presentation of microbials ligands, and 2) Define the role of MR1 SNPs and splice variants in controlling
the recognition of the Mtb infected cell, and will evaluate these variants in clinically relevant outcomes following
exposure to Mtb.
This project contains two Aims:
AIM 1: Define the molecular chaperones necessary for the presentation of Mtb-derived ligands
1a. Determine the molecular chaperones associated with MR1.
1b. Determine the role of riboflavin transporters in the uptake or trafficking of MR1 ligands.
AIM 2: Define the role of MR1 SNPs and splice variants in human susceptibility to TB
2a. Determine the relationship of MR1 SNPs and splice variants and clinical outcomes associated with
exposure to Mtb.
2b. Determine the functional significance of MR1 SNPs.
2c. Determine the relationship of MR1 splice variant expression and the capacity of cells to present MR1
ligands to MR1T cells.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells
-
批准号:10329945
-
项目类别:
-
资助金额:$56.32万
-
财政年份:2019
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
-
批准号:10404652
-
项目类别:
-
资助金额:$67.25万
-
财政年份:2018
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
-
批准号:10164711
-
项目类别:
-
资助金额:$68.33万
-
财政年份:2018
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Lung Resident, MR1-Restricted T Cells: Association with Differential Outcomes Following Exposure to M. Tuberculosis
-
批准号:9593711
-
项目类别:
-
资助金额:$68.72万
-
财政年份:2018
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Human MAIT celis in airway mucosal immune responses to intracellular infections
-
批准号:8880108
-
项目类别:
-
资助金额:$127.78万
-
财政年份:2011
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-infected Cells by CD8+ T Lymphocytes
-
批准号:8072940
-
项目类别:
-
资助金额:$0.88万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-Infected Cells by Non-Classically Restritcted CD8+ T Cells
-
批准号:8195873
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-Infected Cells by Non-Classically Restritcted CD8+ T Cells
-
批准号:7931814
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-Infected Cells by Non-Classically Restritcted CD8+ T Cells
-
批准号:8397519
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-infected Cells by CD8+ T Lymphocytes
-
批准号:8112146
-
项目类别:
-
资助金额:$25.53万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-Infected Cells by Non-Classically Restricted CD8+ T Cells
-
批准号:10343761
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-Infected Cells by Non-Classically Restritcted CD8+ T Cells
-
批准号:8259066
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Multidisciplinary Research Training in Pulmonary Medicine
-
批准号:10670927
-
项目类别:
-
资助金额:$43.94万
-
财政年份:2008
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Multidisciplinary Research Training in Pulmonary Medicine
-
批准号:8607381
-
项目类别:
-
资助金额:$35.34万
-
财政年份:2008
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Multidisciplinary Research Training in Pulmonary Medicine
-
批准号:8857221
-
项目类别:
-
资助金额:$35.88万
-
财政年份:2008
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Multidisciplinary Research Training in Pulmonary Medicine
-
批准号:10442361
-
项目类别:
-
资助金额:$42.96万
-
财政年份:2008
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Multidisciplinary Research Training in Pulmonary Medicine
-
批准号:10088610
-
项目类别:
-
资助金额:$40.81万
-
财政年份:2008
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
HUMAN T CELL RESPONSES TO MYCOBACTERIUM TUBERCULOSIS
-
批准号:6970618
-
项目类别:
-
资助金额:$10.53万
-
财政年份:2004
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-infected cells by CD8+ T lymphocytes
-
批准号:8386558
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2001
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
Recognition of Mtb-infected cells by CD8+ T lymphocytes
-
批准号:6608864
-
项目类别:
-
资助金额:$30.2万
-
财政年份:2001
-
负责人:DAVID M. LEWINSOHN
-
依托单位:
海外基金